We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.78%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.3B
AUM Growth
-$82M
Cap. Flow
-$615M
Cap. Flow %
-7.41%
Top 10 Hldgs %
34.19%
Holding
170
New
23
Increased
24
Reduced
50
Closed
20

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$104M
2
CI icon
Cigna
CI
+$77.7M
3
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$73.5M
4
MOH icon
Molina Healthcare
MOH
+$62.4M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$56.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$125M
2
BIIB icon
Biogen
BIIB
+$88.7M
3
SEM
Select Medical
SEM
+$77.6M
4
MRK icon
Merck
MRK
+$75.8M
5
FOLD
Amicus Therapeutics
FOLD
+$74.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.81%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$401M 4.82%
2,881,103
-243,500
-8% -$30.5M
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
$333M 4.01%
10,889,280
– –
BIIB icon
3
Biogen
BIIB
$30.4B
$322M 3.87%
910,300
-257,600
-22% -$88.7M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$124B
$308M 3.72%
1,600,500
-192,100
-11% -$34.2M
BSX icon
5
Boston Scientific
BSX
$68.5B
$303M 3.65%
7,863,995
-1,710,700
-18% -$59.7M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$294M 3.55%
4,155,891
-257,400
-6% -$17.7M
MRK icon
7
Merck
MRK
$326B
$251M 3.03%
3,714,531
-1,190,109
-24% -$75.8M
CELG
8
DELISTED
Celgene Corp
CELG
$220M 2.66%
2,463,850
-106,800
-4% -$9.44M
AGN
9
DELISTED
Allergan plc
AGN
$219M 2.64%
1,150,405
-135,800
-11% -$24.9M
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
$187M 2.25%
6,439,568
+116,900
+2% +$3.15M
VTRS icon
11
Viatris
VTRS
$20.8B
$175M 2.11%
4,779,600
+1,076,800
+29% +$40.4M
EW icon
12
Edwards Lifesciences
EW
$48.2B
$172M 2.08%
2,971,800
+359,100
+14% +$17.6M
TMO icon
13
Thermo Fisher Scientific
TMO
$214B
$163M 1.96%
668,000
+84,500
+14% +$19.4M
REGN icon
14
Regeneron Pharmaceuticals
REGN
$72.9B
$159M 1.92%
394,400
+21,900
+6% +$8.33M
JAZZ icon
15
Jazz Pharmaceuticals
JAZZ
$16.1B
$149M 1.79%
884,000
-156,100
-15% -$26.8M
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.63B
$138M 1.66%
854,400
+401,800
+89% +$54.9M
HUM icon
17
Humana
HUM
$46.7B
$133M 1.6%
393,000
+320,400
+441% +$104M
CI icon
18
Cigna
CI
$79.6B
$132M 1.59%
633,900
+419,100
+195% +$77.7M
ELV icon
19
Elevance Health
ELV
$83.7B
$130M 1.56%
474,000
-57,800
-11% -$15M
BMY icon
20
Bristol-Myers Squibb
BMY
$130B
$126M 1.51%
2,025,800
-354,500
-15% -$21M
PBYI icon
21
Puma Biotechnology
PBYI
$406M
$124M 1.49%
2,705,181
-27,700
-1% -$1.34M
CMTA
22
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$116M 1.4%
10,425,225
– –
DVA icon
23
DaVita
DVA
$15.4B
$104M 1.25%
1,445,700
-243,700
-14% -$17.2M
INSP icon
24
Inspire Medical Systems
INSP
$1.5B
$103M 1.24%
2,444,221
– –
ILMN icon
25
Illumina
ILMN
$29.2B
$98.2M 1.18%
274,990
-17,476
-6% -$5.6M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2018 Portfolio in Review

As of Q3 2018, OrbiMed held 170 positions worth $8.3B, down 0.98% from $8.38B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $615M in Q3 2018, closing 20 positions and reducing 50 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $125M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Principia Biopharma Inc. Common Stock worth $76.1M.

  • OrbiMed's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 2,605,713 shares worth $76.1M.
  • OrbiMed added most to Humana in Q3 2018, an estimated $104M increase.
  • OrbiMed's biggest Q3 2018 reduction was Biogen, cutting an estimated $88.7M.
  • OrbiMed fully exited Alnylam Pharmaceuticals in Q3 2018, selling an estimated $125M.
  • OrbiMed's ten largest holdings make up 34% of its $8.3B portfolio in Q3 2018.
  • OrbiMed opened 23 new positions and closed 20 in Q3 2018.
  • OrbiMed's portfolio value fell 0.98% quarter-over-quarter to $8.3B.

Based on OrbiMed's 13F filing for Q3 2018, filed 14 Nov 2018.